Skip to main content

Advertisement

Log in

COBIN hypertension programme cost effective in Nepal

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2018 US dollars

References

  • Krishnan A, et al. Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis. The Lancet Global Health 7: e1367-e1374, No. 10, Oct 2019. Available from: URL: https://doi.org/10.1016/S2214-109X(19)30338-9

  • McPake B. The need for cost-effective and affordable responses for the global epidemic of non-communicable diseases. The Lancet Global Health 7: No. 10, Oct 2019. Available from: URL: https://doi.org/10.1016/S2214-109X(19)30375-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

COBIN hypertension programme cost effective in Nepal. PharmacoEcon Outcomes News 838, 6 (2019). https://doi.org/10.1007/s40274-019-6251-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6251-5

Navigation